Holen Sie sich die Stockscreener-App
16.40
3.76%
-0.64
Handel nachbörslich:
16.47
0.07
+0.43%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Sarepta Therapeutics (SRPT) Maintains 'Outperform' Rating as Mizuho Raises Price Target | SRPT Stock News - GuruFocus
Regenxbio Reinforces Case for Its Duchenne Gene Therapy Amid Accelerated Approval Uncertainty - Citeline News & Insights
Sarepta Therapeutics (SRPT) Maintains 'Outperform' Rating as Miz - GuruFocus
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders - BioSpace
Solid Bio’s SGT-003 Data Show DMD Gene Therapy Efficacy Without Liver Toxicity - Citeline News & Insights
Sarepta (NASDAQ:SRPT) Healthcare Tech Buzz In Nasdaq Composite - Kalkine Media
Citigroup Raises Price Target for SRPT but Maintains Sell Rating - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Given New $9.00 Price Target at Citigroup - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Market Sentiment Tied To Nasdaq Futures - Kalkine Media
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Why Is uniQure Stock Skyrocketing Monday? - Benzinga
Sarepta Changes Course, Agrees to Pause Elevidys Shipments - MSN
Assessing Sarepta Therapeutics (SRPT) Valuation After A Difficult Year For Shareholders - Yahoo Finance
Sarepta Therapeutics Stock Pre-Market (+4.7%): Rebounds With Market on Easing Geopolitical Fears - Trefis
SRPT Earnings History & Surprises | EPS & Revenue Results | SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) - ChartMill
Sarepta Stock Pre-Market (+4.7%): Sector Read-Across Ahead of Key Medical Conferences - Trefis
Biopharma’s recent string of CEO splits - Pharma Voice
A Look At Sarepta Therapeutics (SRPT) Valuation After Elevidys Launch Updates And Recovery Story Analyst Commentary - Sahm
Sarepta Therapeutics (SRPT) Is Down 7.0% After CEO Retirement Plan And ELEVIDYS Japan Launch NewsHas The Bull Case Changed? - Sahm
(SRPT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
SRPT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Jefferies Maintains Buy on Sarepta Therapeutics (SRPT) March 03, 2026 - Meyka
Sarepta (SRPT) COO Estepan reports PSU vesting and tax share withholding - Stock Titan
SRPT: 2026 revenue targets remain solid as clinical and commercial initiatives advance toward 2027 - TradingView
SRPT SEC FilingsSarepta Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty - TipRanks
Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight - GuruFocus
Sarepta Therapeutics Eyes 2026 Reset After Rocky Year - TipRanks
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - Yahoo Finance
Wedbush Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $29.00 - MarketBeat
Wedbush Adjusts Sarepta Therapeutics PT to $29 From $34, Maintains Outperform Rating - marketscreener.com
Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from HC Wainwright - MarketBeat
Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Vanguard Group Inc. - MarketBeat
Sarepta (NASDAQ: SRPT) COO exercises stock options, lifts holdings to 200,750 shares - Stock Titan
Sarepta Therapeutics, Inc. (SRPT) Investor Outlook: Understanding the 25.56% Upside Potential - DirectorsTalk Interviews
HC Wainwright & Co. Reiterates Sell Rating for SRPT | SRPT Stock News - GuruFocus
Sarepta Therapeutics 10-K: $2.20B Revenue, $(7.13) EPS - TradingView
Sarepta (NASDAQ: SRPT) details 2025 gene therapy setbacks and big siRNA deal - Stock Titan
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major PlayersAlnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45 - Yahoo Finance
Why Sarepta Therapeutics (SRPT) Is Down 11.2% After CEO Retirement Plan And Japan Gene Therapy LaunchAnd What's Next - Yahoo Finance
Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Sahm
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Insider Monkey
Is Sarepta Therapeutics (SRPT) Pricing Reflect Its Value After Recent Share Price Slide - simplywall.st
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Sarepta (SRPT) COO earns 1,875 PSUs tied to performance milestones - Stock Titan
Wells Fargo & Company Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $38.00 - MarketBeat
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2025 Earnings Call Transcript - Insider Monkey
Erste Asset Management GmbH Has $50.59 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics CEO Ingram to retire by year end - The Mighty 790 KFGO
Sarepta Therapeutics Announces Planned CEO Leadership Transition - The Globe and Mail
Sarepta Therapeutics (SRPT) Q4 Loss Deepens And Tests Bullish Profitability Narrative - simplywall.st
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 9% Following Weak Earnings - MarketBeat
After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral - BioSpace
Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates - Nasdaq
Pharma Leadership Roundup: Sarepta Therapeutics CEO Announces Retirement, Rivus Pharmaceuticals Appoints New CEO - Pharmaceutical Executive
Sarepta CEO Ingram Steps Down As Dystrophy Strikes Close To Home - Citeline News & Insights
Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Sarepta to present Duchenne therapy data at MDA conference By Investing.com - Investing.com South Africa
Sarepta to present Duchenne therapy data at MDA conference - Investing.com
Sarepta seeks new boss amid Doug Ingram retirement - The Pharma Letter
7.5-year Duchenne gene therapy data, caregiver views set for MDA 2026 - Stock Titan
Sarepta CEO Doug Ingram to retire, with company at a crossroads - BioPharma Dive
Sarepta Therapeutics Reports Earnings Miss and Management Transition - Intellectia AI
Sarepta CEO To Jump Ship After 'Tumultuous' YearSarepta Therapeutics (NASDAQ:SRPT) - Benzinga
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):